Table 4.
Baseline univariate predictors of clinical improvement in tocilizumab patients.
| Improved (22 patients) | Not improved (10 patients) | p-value | |
|---|---|---|---|
| Age (years), median (IQR) | 59,5 (51 – 72) | 74 (69.5 – 78) | 0.009 |
| Sex (male), n (%) | 22 (100) | 7 (70) | 0.024 |
| PaO2:FiO2, median (IQR) | 137 (90 – 185) | 86 (68 – 103) | 0.008 |
| Body temperature (°C), median (IQR) | 37.6 (36.5 – 38.3) | 37.5 (37.4 – 38.1) | 0.77 |
| CRP (mg/L), median (IQR) | 128 (69 – 187) | 186 (137 – 2702) | 0.038 |
| LDH (U/L), median (IQR) | 429 (354 – 552) | 446 (426 – 564) | 0.54 |
| NIV, n (%) | 16 (73) | 9 (41) | 0.39 |
| Duration of symptoms (days), median (IQR) | 11 (7 – 14) | 11.5 (10 – 14) | 0.28 |
| CKD, n (%) | 2 (9) | 1 (10) | 0.99 |
| Arterial hypertension, n (%) | 7 (32) | 5 (50) | 0.44 |
| COPD, n (%) | 0 | 1 (10) | 0.31 |
| Cancer, n (%) | 1 (4) | 1 (10) | 0.53 |
| T2DM, n (%) | 3 (14) | 1 (10) | 0.99 |
| CAD, n (%) | 2 (9) | 2 (20) | 0.57 |
| Re-treatment, n (%) | 5 (23) | 4 (40) | 0.41 |
NIV = non-invasive ventilation. CRP = C-reactive protein. LDH = lactate dehydrogenase. CKD = chronic kidney disease. COPD = chronic obstructive pulmonary disease. T2DM = type-2 diabetes mellitus. CAD = coronary artery disease.